Loading
Cardiovascular Disease and Adiposity · Journal article
Scientific Reports · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
In a rat metabolic syndrome model, dapagliflozin reduced inducible ventricular arrhythmias and shortened action potential duration, accompanied by epicardial fat reduction, antifibrotic effects, and modest biomarker changes. This is mechanistic preclinical evidence that does not establish clinical efficacy or safety in humans with HFpEF.
Three-group preclinical animal model study in rats. Male Wistar rats; three experimental groups (wild-type control, MetS, MetS-dapa). Intervention: Dapagliflozin treatment in metabolic syndrome rats. Compared with: MetS group without dapagliflozin; wild-type control group.
Dapagliflozin reduced VA inducibility, episode frequency, and duration compared with MetS group Dapagliflozin shortened APD 70 and reduced maximum slope of APD restitution Dapagliflozin reduced body weight, blood pressure, and epicardial fat accumulation versus MetS
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding suggests a potential antiarrhythmic mechanism of SGLT2 inhibition in metabolic cardiomyopathy, but human studies are required before clinical applicability can be assessed.
Animal model study with mechanistic findings on arrhythmia reduction; lacks human validation and hard clinical outcomes needed for stronger evidence grading.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding suggests a potential antiarrhythmic mechanism of SGLT2 inhibition in metabolic cardiomyopathy, but human studies are required before clinical applicability can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Metabolic syndrome (MetS) and obesity contribute to cardiometabolic heart failure with preserved ejection fraction (HFpEF) and ventricular arrhythmia (VA), but the effects of sodium-glucose cotransporter-2 (SGLT2) inhibition on VA remain unclear. We investigated the antiarrhythmic effects of dapagliflozin in a rat model of cardiometabolic HFpEF. Male Wistar rats were assigned to wild-type control (WT), high-fat/high-glucose diet-induced MetS (MetS), or MetS with dapagliflozin treatment (MetS-dapa) groups. VA was induced by in vivo programmed electrical stimulation, and ventricular electrophysiology was assessed by optical mapping. Dapagliflozin reduced body weight, blood pressure, epicardial fat accumulation, VA inducibility, episode frequency, and duration compared with the MetS group. Electrophysiologically, dapagliflozin shortened action potential duration at 70% repolarization (APD 70 ), reduced the maximum slope of APD restitution, and improved conduction-direction heterogeneity without significantly altering mean conduction velocity. Dapagliflozin also reduced epicardial adipose deposition, plasma free fatty acids, interstitial fibrosis, and TNF-α levels, while increasing SOD activity and KCNN2 levels. Biomarker analysis showed a modest increase in SIRT1 and a slight decrease in HIF1α after dapagliflozin treatment. These findings suggest that dapagliflozin reduces ventricular arrhythmogenesis through epicardial fat remodeling, antifibrotic and anti-inflammatory effects, and electrophysiological stabilization, accompanied by modest SIRT1–HIF1α-related biomarker changes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.